ATLASense Biomed Earns Henry Ford Health System’s Global Health Tech Challenge Top Prize
Congratulations to Dan Atlas and Tal OR for winning the 2020 Henry Ford Health System’s Global Health Tech Challenge ! ATLASense Biomed, Israeli-based start-up company,
Nano-X Signs $174M Australian Distribution Agreement
Israel-based medical imaging startup Nano-X Imaging Ltd. has signed an exclusive distribution agreement with Prestons, Australia-based the Gateway Group. As part of the agreement, Gateway
JLM Cancer Treatment Company Kahr Medical raises $18m
KAHR Medical Ltd., a biopharmaceutical company developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins known as Dual Signaling Proteins (“DSP”) today announced
DouxMatox among the top 50 Cos Worldwide in the SVG Ventures-THRIVE 2020 Food Tech Sector
DouxMatox was selected among the top 50 companies worldwide in the Foodtech and Agtech (agriculture tech) sectors in 2020, put together by SVG Ventures-THRIVE and
Future Meat listed on SVG Ventures THRIVE Top 50 AgTech & FoodTech Cos worldwide
Future Meat Technologies was listed among two separate lists highlighting the top 50 companies worldwide in the Foodtech and Agtech (agriculture tech) sectors in 2020,
Argaman Technologies Viral Deactivation Face Masks to Hong Kong to fight Coronavirus!
Jerusalem based Argaman Technologies, Ltd. presents its Viral Deactivation Face Masks which are headed to Hong Kong to fight the Coronavirus. The Argaman Face Masks
RenalSense starts Delivery of its First Orders of Clarity RMS in Europe
RenalSense has started commercial sales of its Clarity RMS™ system in Europe with its distribution partner Fresenius Medical Care (Bad Homburg). The Clarity RMS received
Genetika+ Won Three International Awards in 2019!
Genetika + is a Jerusalem based biotech start-up developing cutting edge technology to determine which anti-depressant is best suited to each patient. When Treating a
Good News from the NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax’s M-001 Universal Influenza Vaccine Candidate
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax’s M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials Data published on Clinicaltrials.gov
